Identifying clinical features and molecular characteristics of the endometrial clear cell carcinoma.
HER-2
TAF1
TCGA
endometrial clear cell carcinoma
molecular characteristics
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
08
2023
accepted:
27
10
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
The aim of this study was to verify TCGA subtypes in endometrial clear cell carcinoma (ECCC) and determine their clinical and molecular characteristics. We summarized and compared the clinical features of 28 clear cell carcinoma and 112 endometrioid carcinoma patients. Of the 28 ECCCs, 19 underwent TCGA classification, and other markers (ER, PR, ARID1A, ARIB1B, TAF1, and HER-2) were also detected by IHC, and outcomes were assessed. Compared to endometrioid carcinoma, ECCC had an older age of onset (median age, 64.5 years, range 31-81 years), higher rate of myometrial invasion (42.8% vs. 21.5% in endometrioid carcinoma), LVSI (33% vs. 16%), and more advanced FIGO stage. Among the ECCCs, LVSI was a poor prognostic factor. TCGA classification was performed for 19 ECCCs: two POLEmut cases (10.5%), three MMRd (15.8%), 11 p53wt (57.9%), and three p53abn (15.8%). Of the 19 ECCCs, six (31.6%) showed HER-2 positive expression, and eight (42.1%) had TAF1 expression loss. ECCCs possessed HER-2 and TAF1 expression had worse outcomes. Our study summarized the clinical features of ECCC. The outcomes of patients with ECCC with TCGA subtypes differed from those of patients with endometrioid carcinoma. HER-2 and TAF1 may be new prognostic factors.
Identifiants
pubmed: 38045002
doi: 10.3389/fonc.2023.1286176
pmc: PMC10691759
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1286176Informations de copyright
Copyright © 2023 Cai, Han and Guo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Med Rep. 2016 May;13(5):3828-34
pubmed: 26985869
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
Iran J Pathol. 2019 Fall;14(4):322-328
pubmed: 31754363
Int J Gynecol Cancer. 2017 Oct;27(8):1714-1721
pubmed: 28945214
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
pubmed: 11252954
Arch Gynecol Obstet. 2017 Jan;295(1):189-195
pubmed: 27549092
J Pathol. 2017 Oct;243(2):230-241
pubmed: 28718916
N Engl J Med. 2019 Sep 26;381(13):1284-1286
pubmed: 31502769
J Clin Oncol. 2006 May 20;24(15):2376-85
pubmed: 16710036
Genes Dev. 2017 Nov 1;31(21):2162-2174
pubmed: 29203645
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
J Clin Oncol. 2013 Jul 10;31(20):2607-18
pubmed: 23733771
Pathol Oncol Res. 2017 Jan;23(1):125-130
pubmed: 27571988
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Sci Rep. 2018 Mar 15;8(1):4630
pubmed: 29545534
Hum Pathol. 2019 Oct;92:10-17
pubmed: 31269413
Cancer. 2017 Sep 1;123(17):3261-3268
pubmed: 28485815
Cancer. 1996 Oct 15;78(8):1740-7
pubmed: 8859187
Gynecol Oncol. 2017 Feb;144(2):243-249
pubmed: 27993480
J Cancer Res Ther. 2018 Sep;14(Supplement):S622-S627
pubmed: 30249878
Gynecol Oncol. 2014 Sep;134(3):516-22
pubmed: 25019570
Am J Surg Pathol. 2019 Apr;43(4):531-537
pubmed: 30585826
Am J Surg Pathol. 2013 Jun;37(6):874-81
pubmed: 23629444
Am J Surg Pathol. 2013 Sep;37(9):1421-32
pubmed: 24076778
Gynecol Oncol. 2022 Mar;164(3):658-666
pubmed: 35063279
Int J Gynecol Pathol. 2015 Jan;34(1):74-84
pubmed: 25473756
Gynecol Oncol. 2020 Jul;158(1):3-11
pubmed: 32331700
Front Oncol. 2023 Mar 09;13:1167088
pubmed: 36969075
J Cell Physiol. 2020 Jan;235(1):611-618
pubmed: 31283007
Cancer. 2017 Sep 1;123(17):3216-3218
pubmed: 28485840
Histopathology. 2015 Apr;66(5):664-74
pubmed: 25308272
Histopathology. 2020 Jan;76(2):336-338
pubmed: 31433862